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ABSTRACT: The mushroom Agaricus blazei Murrill was discovered in Piedade, state of São Paulo, Brazil,
and sent to Japan to be studied for its medicinal properties. Studies in guinea pigs revealed antitumor properties,
triggering Japanese importation of A. blazei from Brazil. Because of its high price on the international market,
many companies and rural growers produce A. blazei as alternative crop to increase income, but because
interest in this mushroom occurred suddenly there has not been enough time for the scientific community to
investigate it and, technology used for its cultivation is still based on empirical rules. There are also some
contradicting data regarding the classification of this mushroom, and its antitumor properties still need to be
confirmed in humans.
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VERDADES E MITOS SOBRE O COGUMELO Agaricus blazei
RESUMO: O cogumelo Agaricus blazei Murrill foi descoberto na cidade de Piedade, Estado de São Paulo,
Brasil, e enviado para o Japão para o estudo das suas propriedades medicinais. Com a descoberta das suas
propriedades antitumorais, comprovadas em cobaias, o Japão passou a importar esse cogumelo do Brasil.
Devido ao seu elevado preço no mercado internacional, muitas empresas e produtores rurais passaram a
buscar nesse cogumelo uma nova alternativa de renda. Diante de um interesse tão repentino, não houve
tempo para que a comunidade científica pesquisasse o assunto, de maneira que a tecnologia de cultivo é ainda
muito empírica. Além disso, existem informações contraditórias acerca da classificação desse cogumelo e as
suas propriedades antitumorais ainda precisam ser confirmadas em seres humanos.
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INTRODUCTION
From the early days of civilization, man has used
fungi for the production of fermented foods and bever-
ages, or directly as food. In Ancient Egypt, fermentation
was considered a gift from the god Osiris, while ancient
Romans attributed the emergence of mushrooms and
truffles to lightening bolts cast to the earth by Jupiter
(Alexopoulos et al., 1996).
For centuries, Asians have attributed curative
properties to some mushrooms. Reports from China since
about 500 BC, on the medicinal properties of Ganoderma
lucidum (known in China as reishi) extracts, especially its
anti-cancer properties, have been passed on generation to
generation (Mizuno et al., 1995a; 1995c), and since the
Ming dynasty (1620 AD), there have been reports on the
medicinal properties of Lentinula edodes (shiitake) mush-
rooms, considered an elixir of life and possessing the ability
to enhance ‘vital energy’ and cure colds (Mizuno, 1995a).
In the late Twentieth Century, researchers in Ja-
pan demonstrated the antitumor effects of a Brazilian
mushroom, identified as Agaricus blazei Murrill, which
became subject of studies by several research groups
(Kawagishi et al., 1988; 1989; Osaki et al., 1994; Itoh et
al., 1994; Higaki et al., 1997; Ito et al., 1997). These stud-
ies increased interest for A. blazei among the Japanese,
and so it began to be imported from Brazil, enticing many
Brazilian mushroom growers to begin cultivating A.
blazei which became an excellent source of increased in-
come. However, because of the reported medicinal im-
portance of A. blazei, some producers registered names
or brands indicating that this mushroom was their own
product, making difficult the scientific identification of
A. blazei strains. There is therefore a need to clarify sev-
eral points regarding A. blazei, so that this important
mushroom is not monopolized by only a few producers
but can be freely cultivated by small farmers, who have
actually been growing it for a long time in Brazil. More
widespread cultivation of A. blazei would mean that this
mushroom would be cheaper for Brazilian consumers,
who cannot at present afford to buy it, and cease to be a
product for export only.
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Mushrooms as a source of antitumor substances
According to Mizuno et al. (1995a), one of the
pioneer studies regarding the antitumor activity of mush-
rooms was published by Ikegawa et al. (1968). Theses
authors described potent antitumor activity in aqueous
extracts of some mushrooms, including members of the
Polyporaceae family, to which Ganoderma lucidum be-
longs. Later on, Chihara et al. (1970) reported the purifi-
cation of shiitake polysaccharides with high antitumor
activity. In the sequence, one of these polysaccharides,
lentinan, started being commercialized by a Japanese
company for the treatment of stomach cancer (Mizuno et
al., 1995b). From that on, numerous reports have been
published describing the isolation and study of substances
with medicinal properties from a large number of mush-
room species. In addition to lentinan, two other cytostatic
drugs have been isolated in Japan: krestin, produced by
Coriolus versicolor mycelium and used in the treatment
of cancers of the gastrointestinal tract, lung and breast;
and schizophyllan, (or Sonifilan), extracted from the cul-
ture medium of Schizophyllum commune and used in the
treatment of cervical cancer (Mizuno et al., 1995b).
Although there is no commercial production of
the purified compound responsible for the medicinal prop-
erties of A. blazei, several studies have been carried out
to isolate and characterize A. blazei polysaccharides with
antitumor activity (Kawagishi et al., 1989; Mizuno et al.,
1990a; 1990b; Ito et al., 1997; Fujimiya et al., 1999).
Based not only on indigenous or Oriental traditions, but
also on experiments in which many mushrooms have been
screened for substances with pharmacological properties,
it is currently accepted that host edible mushrooms have
some pharmacological property.
One of the great hurdles in making the medici-
nal properties of mushrooms more widely known is that
many of the earlier studies were published in Japanese,
and many of the clinical studies published in Oriental
journals do not last for long (Mattila et al., 2000). Longer
studies covering the entire lifespan of the test animals are
then needed to assess the medicinal properties of mush-
rooms.
The situation in Brazil
Contrasting to Asian, European, and North
American countries, the consumption of mushrooms in
Brazil has always generally been restricted to small eth-
nic communities or to higher economic and/or cultural
status groups. The most widely consumed mushroom
worldwide is Agaricus bisporus, which is also the most
popular mushroom eaten in Brazil, although because of
its relatively high price, the use of A. bisporus its gener-
ally limited to gourmet cuisine. Even though medicinal
plants are widely used in Brazil, there is no traditional
use of mushrooms in Brazilian practical medicine, al-
though there has recently been greater interest in mush-
room consumption with the growing awareness of the iso-
lation of substances with medicinal properties from vari-
ous mushroom species. Besides their medicinal proper-
ties, edible mushrooms have been considered a health
food because they are low in fat, rich in vitamins and
amino acids and, compared to most vegetables, high in
protein (Crisan & Sands, 1978). With the greater popu-
larization of these properties and of their culinary quali-
ties there has been a slow but noticeable change in the
habits of Brazilians regarding the consumption of mush-
rooms, and as a result, there is currently a considerable
number of Brazilian mushroom growers interested not
only in A. bisporus but also in other mushrooms, such as
Pleurotus ostreatus (hiratake and shimeji), Pleurotus
sajor-caju (houbitake) and, especially, Lentinula edodes
(shiitake), all valued not only for their medicinal proper-
ties but also for the preparation of gourmet food.
Since the 1990s, there has been a growing inter-
est in Brazil in the cultivation not only of the mushrooms
above mentioned but also in the ‘new’ mushroom spe-
cies, discovered in the Brazilian town of Piedade in the
Brazilian state of São Paulo in 1960 by a grower and re-
searcher named Furumoto, who sent it to Japan in 1965
for investigation (Mizuno, 1995b). This mushroom was
identified as Agaricus blazei Murrill by the Belgian sci-
entist Dr. Heinemann in 1967 (Heinemann, 1993; Mizuno,
1995b) and was given the common name of
Himematsutake in Japan, while in Brazil it was named
the Piedade mushroom after the town where it was dis-
covered, and later known as either medicinal mushroom
or Sun Mushroom® (Cogumelo do Sol® in Portuguese) in
Brazil and the Royal Sun Agaricus® in other countries.
After the death of Mr. Furumoto, cultivation of A. blazei
was abandoned and it was only in 1990 that its cultiva-
tion was revived as a result of the interest of some Japa-
nese businessman who brought A. blazei strains back
from Japan where they had been used in antitumor ac-
tivity studies (Fujimiya et al., 1998; 1999; Kawagishi et
al., 1988; 1989; Osaki et al., 1994; Itoh et al., 1994; Ito
et al., 1997). According to Ernesto N. Uryu, an agrono-
mist at an organization for technical assistance
(Coordenadoria de Assistência Técnica Integral - CATI,
Sorocaba, São Paulo, Brazil) and a contemporary of Mr.
Furumoto, the mushrooms originally grown by Mr.
Furumoto had a very strong aroma and flavor which made
them difficult to eat, but the strains brought from Japan
had lost many of their original characteristics and had ac-
quired a more pleasant smell, a lighter coloration, and
were bigger (personal communication, 1998).
Because of the interest of the Japanese market a
new phase in the cultivation of mushrooms was initiated
in Brazil in which A. blazei had the status of an export
product, with higher prices in comparison to other mush-
rooms, and A. blazei began to represent an optimal alter-
native cash crop for small rural growers. The lack of sci-
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entific studies on A. blazei meant that it was cultivated
empirically based on the cultivation of A. bisporus, which
has a very similar life cycle, although differing in the
terms of environmental factors, A. bisporus being a tem-
perate species with optimal fruit body initiation at 17°C,
while A. blazei is a tropical species, with optimal fruit
body initiation at 25°C.
Several Brazilian publicly funded institutions are
currently engaged in research on A. blazei, studying bio-
chemical, physiological and genetic aspects of this fun-
gus and carrying out applied research on the selection of
compost, soil casing techniques and optimization of the
environmental conditions needed for the growth of A.
blazei. Such research means that the cultivation of this
mushroom can be carried out on a scientific basis taking
into account the particularities of the species.
Studies describing the antimutagenic properties
of A. blazei have already been published in Brazil.
Delmanto et al. (2001) used mice to show the antimu-
tagenic activity of an aqueous extract of A. blazei, anti-
mutagenic activity only being observed when the extract
was obtained by mixing extracts from three different A.
blazei strains. These results indicated that differences be-
tween strains or growth conditions might influence the
medicinal properties of A. blazei. Menoli et al. (2001)
observed that a mixture of extracts from the same strains
described by Delmanto et al. (2001) showed antimu-
tagenic activity against Chinese hamster V79 lung cells
treated with methyl methanesulfonate. Research has also
been published on clinical studies employing the mush-
room described as Agaricus sylvaticus (Gennari, 2000a)
(which may in fact be A. blazei), including studies of the
effects of this mushroom on cancer and AIDS (Gennari,
2000b) and on increased numbers of natural killer cells
in cancer patients (Gennari et al., 2001).
Medicinal mushrooms: science versus profit
With the discovery of the antitumor properties of
A. blazei, many companies began to commercialize the
dehydrated mushroom for export and, on a smaller scale,
for the Brazilian market. In Brazil, a prominent feature
of the mushroom industry has been the broad popular-
ization of the medicinal properties-bearing mushrooms,
but because of the unethical way that these medicinal
properties were marketed, the health claims have been
viewed with suspicion. Some accusations have been
made, especially on television, that companies were sell-
ing mushroom products and promising results that had not
yet been proved scientifically because of the lack of re-
search showing the same antitumor activity in humans as
had been demonstrated in animals. Decree 396/1999 of
the Brazilian Ministry of Health prohibits the sale of
foods with medicinal properties or the suggestion that
they can be used for the treatment or prevention of dis-
eases.
Another negative aspect created by purely eco-
nomic interests is the attempt to exclusively exploit this
mushroom. Despite the fact that the term Cogumelo do
Sol® became popular among growers as a common name
for the species Agaricus blazei, the name Cogumelo do
Sol® was registered as a trademark by a company in São
Paulo. In addition to appropriating a name already in
common use, the same company reported that, based on
a study by Dr. Pegler of the Royal Botanic Gardens Lon-
don (see below), their Cogumelo do Sol® was very simi-
lar to Agaricus sylvaticus Shaeffer and that it was the re-
sult of the fusion of several fungi and a hybrid not found
in nature. There is a series of contradictions in the infor-
mation regarding A. blazei presented by this company.
First, there is no report whatsoever in the scientific litera-
ture of a fungus with the name Agaricus sylvaticus Shaeffer
although there is an Agaricus silvaticus Schaeffer. Because
of the similarity between these names it is almost certain
that the so-called A. sylvaticus Shaeffer was identified as
a species (Agaricus silvaticus Schaeffer) already known for
decades. Someone, probably by mistake, took it upon them-
selves to change or omit some letters, substituting the let-
ter ‘i’ in the scientific name by ‘y’ and omitting the letter
‘c’ in the author’s name. The mushroom A. silvaticus is
described in the literature as being native to temperate re-
gions, contrary to what is known for the mushroom found
in the Piedade region of São Paulo and which was sent to
Japan for identification, this mushroom growing well at
about 25°C. Some samples of the Piedade mushroom were
sent from Japan to Dr. Heinemann in Belgium, who iden-
tified them as Agaricus blazei Murrill, while the Biologi-
cal Institute of São Paulo sent other samples to Dr. Pegler
who Fellippe Jr. (1999) erroneously reported as having
identified them as Agaricus sylvaticus Shaeffer. It looks like
the samples were identified as different species and that
Dr. Pegler probably did not consider it a new species but
that it was similar to Agaricus silvaticus Schaeffer.
The few scientific reports on the Cogumelo do
Sol®, citing it as the Royal Sun Agaricus®, refer to it as a
natural variant of A. blazei, but if this is true, then royal
agaricus could never have been considered as a new spe-
cies but only as one of the numerous strains of A. blazei.
As far as we know no paper has been published in scien-
tific journals on the antitumor properties, or any other
therapeutic action, of A. silvaticus, although some internet
sites mention it as a poisonous species capable of caus-
ing flue-like symptoms.
The claim that the Cogumelo do Sol® was a re-
sult of the fusion of various fungi does not have any sci-
entific support, because the fusion of fungi to produce a
new species does not readily occur. If this did indeed hap-
pen there should have been a detailed description of the
methodology, preferably published in a peer-reviewed
journal, and the fact that there is no scientific support for
strain fusion casts doubts on the consistency of much of
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the information published on the sun mushroom, which
may not necessarily be true.
Considering all the above, it is evident that there
is a need to clarify the identity of the Cogumelo do Sol®.
Dr. Mizuno, one of the icons of Japanese medicinal mush-
room research, referred to what is now known as Sun
Mushroom (Cogumelo do Sol®) as the Royal Agaricus or
Agaricus blazei Murrill (Mizuno, 2000), while in a tech-
nical study, Stamets (2000) referred to it as the Royal Sun
Agaricus® or A. blazei Murrill. Scientific recognition of
the medicinal properties attributed to the Sun Mushroom
(Cogumelo do Sol®) always refer to it as A. blazei Murrill,
this being the nomenclature adopted by the scientific
community in both Brazil and Japan.
Colauto et al. (2002) genetically characterized
several A. blazei Murrill isolates using random amplified
polymorphic DNA (RAPD) and found little genetic vari-
ability between the isolates, with isolates ABL 97/11,
ABL 99/25 and ABL 99/29 being identical and isolates
ABL 99/28 and ABL 99/26 (isolate Jun 17, which has
been used in studies in Japan and at the University of the
State of São Paulo, Brazil) being more divergent, isolate
ABL 99/26 showing the greatest genetic distance. Al-
though there is a close genetic relationship between the
strains commercialized in Brazil, it is possible to detect
some genetic variability among them. From our point of
view, it would be very interesting if the mushroom com-
mercialized as Agaricus sylvaticus could be genetically
compared with all known strains of A. blazei to establish
its genetic distance.
Since Agaricus blazei Murrill is of North
America origin, Wasser et al. (2002) has proposed that
the Piedade mushroom constitutes a new subspecies,
Agaricus blazei Heinemann native to South America. In
fact Wasser et al. go further and suggest that A. blazei
Murrill and A. blazei Heinemann represent two differ-
ent species and that A. blazei Heinemann should be re-
named as Agaricus brasiliensis S. Wasser, M. Didukh,
de Amazonas et Stamets sp. Nov., syn: A. blazei Murrill
ss. Heinemann., Bull. Jard. Bot. Belg. 62: 365-368,
1993. The synonym A. blazei Murril ss. Heinem may be
more useful commercially for the producers because the
Piedade mushroom is well-known by the name A. blazei
not only in Brazil but also in Japan, which is the main
market for this mushroom, changing its name to one
more obviously Brazilian could affect consumer percep-
tion of this product.
FINAL CONSIDERATIONS
Whether or not the mushroom commercialized
exclusively as the ‘Sun Mushroom’ or the ‘Royal Agari-
cus’ possesses medicinal properties is not disputed here.
Instead, what we are questioning is the lack of consis-
tency in the taxonomy of the species and its origin.
While it is important to have clinical studies of the me-
dicinal properties of mushrooms it is also important to
have a solid scientific basis in terms of microbiology and
genetics and health professionals who carry out such
studies need the support of professionals with taxonomic
experience to avoid the use of inappropriate terms and
expressions. Another important point is that these pro-
fessionals should be objective and not compromised by
the need to produce the results desired by commercial
interests.
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